1. Introduction {#sec1-ijms-21-03793}
===============

The recently worldwide pandemic named COVID-19 (COronaVIrus Disease 2019) has spread rapidly since it emerged in Wuhan (China) in December 2019. SARS-CoV-2 has been identified as the pathogen responsible for the outbreak of an atypical pneumonia whose symptoms range from mild effects such as fever, dry cough, fatigue, dyspnea, difficulty breathing, to severe progressive pneumonia, multiorgan failure and death \[[@B1-ijms-21-03793]\]. Since the outbreak of SARS-CoV-2, the World Health Organization (WHO) has declared a state of global health emergency. Thus, as of the 15th of May 2020, the total number of confirmed cases of COVID-19 has risen to 4,434,590 in at least 188 different countries. Likewise, more than 301,937 deaths and 1,583,929 cases of recovery have been reported according to the Johns Hopkins Coronavirus map tracker \[[@B2-ijms-21-03793]\] at <https://coronavirus.jhu.edu/map.html>. The risk of severe cases increases in elderly patients with previous pathologies, such as heart failure or diabetes (i.e., 89.5% of deaths in Italy for COVID-19 have been among people over 70 years old) \[[@B3-ijms-21-03793]\].

The pathogen that caused the pandemic has been identified as a novel coronavirus which belongs to the *β-coronavirus* family; it is related to acute respiratory syndrome coronavirus (SARS-CoV), which caused another outbreak in 2003 \[[@B4-ijms-21-03793],[@B5-ijms-21-03793]\]. Currently, there are no targeted therapeutics or effective treatments against this new virus. Because of that, the scientific community is making great efforts to investigate different mechanisms to interfere with the virus' metabolism. As a consequence, several antiviral drugs used in patients with similar viral infections have been tested in recent clinical trials against COVID-19, including Remdesivir (designed for the Ebola virus \[[@B6-ijms-21-03793]\]), Lopinavir/Ritonavir (designed for the HIV \[[@B1-ijms-21-03793]\]), chloroquine and hydroxychloroquine (designed for malaria \[[@B6-ijms-21-03793]\]) and Tocilizumab (designed for rheumatoid arthritis \[[@B7-ijms-21-03793]\]), among others. Nevertheless, the efficacy of some drugs remains controversial. This is the case with a clinical trial involving Lopinavir/Ritonavir, which reported that no benefits were observed with this treatment compared to standard care \[[@B1-ijms-21-03793]\].

The characterization of main protease (M-pro), also known as chymotrypsin-like protease (3CL-pro), has emerged as one of the key targets for the development of antiviral therapies aimed at blocking the life cycle of the coronavirus \[[@B4-ijms-21-03793],[@B8-ijms-21-03793],[@B9-ijms-21-03793],[@B10-ijms-21-03793]\]. M-pro is found in the polyprotein ORF1ab of SARS-CoV-2 and is essential for the replication of the virus. This protease is involved in the cleavage of polyproteins, a process that produces nonstructural proteins that are part of the replicase-transcriptase complex \[[@B8-ijms-21-03793],[@B10-ijms-21-03793]\]. The sequence of the M-pro enzyme has a high identity (i.e., \>96%) with SARS-CoV, except for a key residue (i.e., Ala285Thr), which may contribute to the high infectivity of the virus \[[@B11-ijms-21-03793]\]. Moreover, a high superposition correlation (with a value of 0.44 Å for C^α^ RMSD) has been found between the M-pro structure SARS-CoV (i.e., PDBid 3D62) and the recently crystallized structure of SARS-CoV-2 (i.e., PDBid 6LU7) \[[@B9-ijms-21-03793],[@B12-ijms-21-03793]\]. Therefore, besides the fact that this enzyme only exists in the virus and not in humans \[[@B8-ijms-21-03793]\], the high conservation of M-pro among the related viruses and its importance in the replication of the virus makes this enzyme an attractive target for potential antiviral drugs \[[@B12-ijms-21-03793]\]. As a result, the structure of M-pro has been recently solved in different conditions by X-ray crystallography.

Computational approaches can make a great contribution to drug discovery by reducing cost and time (especially for emerging diseases such as COVID-19) and speeding up analyses of target interactions with drug candidates \[[@B13-ijms-21-03793]\]. Consequently, different computational studies have been published in order to better understand the mechanism of M-pro and try to inhibit its function \[[@B4-ijms-21-03793],[@B5-ijms-21-03793],[@B10-ijms-21-03793],[@B12-ijms-21-03793],[@B14-ijms-21-03793],[@B15-ijms-21-03793],[@B16-ijms-21-03793],[@B17-ijms-21-03793],[@B18-ijms-21-03793],[@B19-ijms-21-03793],[@B20-ijms-21-03793],[@B21-ijms-21-03793]\]. Nevertheless, it is important to highlight the fact that, despite the high level of similarity of SARS-CoV-2 with other members of the coronavirus family, their binding sites have differences in shape and size which mean that repurposing SARS drugs may not be successful, and enhanced sampling should be considered \[[@B1-ijms-21-03793],[@B19-ijms-21-03793]\]. Consequently, although the development of a more specific inhibitor is highly desirable, in the absence of an effective treatment, drug repurposing becomes an attractive solution, because it reduces the time and cost of drug development \[[@B22-ijms-21-03793]\]. This strategy is a promising way to explore alternative indications and to identify new targets for existing drugs which have already been established as safe. As the safety profiles of these drugs have already been demonstrated, clinical trials for alternative indications are cheaper, potentially faster and carry less risk than traditional drug development \[[@B22-ijms-21-03793]\].

Therefore, the main goal of this study is to apply an original virtual screening (VS) protocol in order to identify high affinity docked poses that are simultaneously predicted by three different docking programs. This allows us to rapidly identify commercial drugs that have high potential to inhibit M-pro, and subsequently, be tested as a treatments against COVID-19.

2. Results and Discussion {#sec2-ijms-21-03793}
=========================

2.1. Structural Description of M-Pro and Report of Known Mutations in Its Structure {#sec2dot1-ijms-21-03793}
-----------------------------------------------------------------------------------

SARS-CoV-2 M-pro is a homodimeric protein with two subunits related by a crystallographic 2-fold symmetry axis (see [Figure 1](#ijms-21-03793-f001){ref-type="fig"}A) \[[@B9-ijms-21-03793]\]. Each subunit (also called *protomer*) has a length of 306 residues and is formed by three domains (i.e., domain I from residues 8 to 100, domain II from residues 101 to 184 and domain III from residues 199 to 306). Domains I and II share the same fold (an antiparallel six-stranded β-barrel structure), whereas domain III is formed by five α-helices arranged into a largely antiparallel globular cluster. Domains II and III are connected by a long loop formed by residues from 185 to 198. The substrate-binding site of M-pro is located at a cleft between domains I and II, whereas domain III is involved in regulating M-pro dimerization through an intersubunit salt-bridge between Glu290 (from one protomer) and Arg4 (from the other protomer) \[[@B8-ijms-21-03793]\]. The formation of this dimer is essential for M-pro activity because the N-terminal residue of one protomer (i.e., Ser1) interacts with the Glu166 of the other, and thus, helps to form the S~1~ subsite of the substrate-binding pocket \[[@B8-ijms-21-03793]\].

The enzyme has a catalytic dyad formed by His41 and Cys145. As in any protease, other important subsites at the M-pro binding site are S~3~, S~2~, S~1~ and S~1~′, that are occupied, respectively, by the P~3~, P~2~, P~1~ and P~1~′ residues of its peptidic substrate (where the point of peptide cleavage is at the peptide bond that binds residue P~1~ with residue P~1~′). Thus, according to Tang et al. \[[@B12-ijms-21-03793]\], S~3~ is formed by Met165, Leu167, Gln189, Thr190 and Gln192 (see yellow residues in [Figure 1](#ijms-21-03793-f001){ref-type="fig"}B); S~2~ is formed by Met49, Tyr54, His164, Asp187 and Arg188 (see cyan residues in [Figure 1](#ijms-21-03793-f001){ref-type="fig"}B); S~1~ is formed by Ser1 (from the other protomer), Phe140, Leu141, Asn142, His163 and Glu166 (see red residues in [Figure 1](#ijms-21-03793-f001){ref-type="fig"}B); and S~1~' is formed by His41, Gly143, Ser144 and Cys145 (see green residues in [Figure 1](#ijms-21-03793-f001){ref-type="fig"}B) \[[@B12-ijms-21-03793]\]. Other important residues identified by different authors at the M-pro binding site are Thr24, Thr25, Pro168, His172, Phe185 and Ala191 (see magenta residues in [Figure 1](#ijms-21-03793-f001){ref-type="fig"}B) \[[@B8-ijms-21-03793],[@B9-ijms-21-03793]\].

According to the data obtained from GISAID \[[@B23-ijms-21-03793]\], 16 missense mutations have been identified to date in the SARS-CoV-2 gene that codes for M-pro (see [Table 1](#ijms-21-03793-t001){ref-type="table"}). For the moment, these mutations do not affect residues at the binding site, although some of them (i.e., Ala173, Pro184 and Ala193) occur at its proximity (see [Figure 1](#ijms-21-03793-f001){ref-type="fig"}A).

![Overview of the main structural features of the SARS-CoV-2 M-pro. Panel (**A**) shows a general overview of the M-pro homodimeric structure (PDBid 6W63) and the relative location of the missense mutations shown in [Table 1](#ijms-21-03793-t001){ref-type="table"}. The domain structure for one of the two protomers is also shown (with domain I in red, domain II in blue and domain III in green). Panel (**B**) shows the most important residues from the different subsites in the context of the binding site. Thus, the residues from the S~3~, S~2~, S~1~ and S~1~' subsites are shown in yellow, cyan, red and green, respectively. Other important residues at the binding site that have not been assigned by Tang et al. to any of these subsites are shown in magenta. This figure was obtained with the help of the Maestro program \[[@B24-ijms-21-03793]\].](ijms-21-03793-g001){#ijms-21-03793-f001}

Many M-pro structures have been recently deposited at the PDB (see [Table S1](#app1-ijms-21-03793){ref-type="app"}). The first M-pro structure that was delivered by the PDB was 6LU7 \[[@B9-ijms-21-03793]\] and, therefore, this has been the PDB file of choice for the different VS papers or structure-based drug designs reported that do not use homology models \[[@B5-ijms-21-03793],[@B12-ijms-21-03793],[@B21-ijms-21-03793],[@B25-ijms-21-03793],[@B26-ijms-21-03793]\]. [Figure 2](#ijms-21-03793-f002){ref-type="fig"} shows that when 6LU7 is superposed to 6W63 (M-pro bound to a noncovalent inhibitor) or to 6M03 (free enzyme), only minor structural changes affect the binding site structure: (a) Met49/Arg188 (S~2~ subsite) and Met165/Gln189 (S~3~ subsite) show totally different conformations of their sidechains (while keeping Met49 and Arg188 main chains coincident); (b) all the residues at the S~3~ subsite, Pro168 and Ala191 have their main chain slightly displaced in one or in all three structures; and (c) Ser1 and Asn142 (S~1~ subsite) show a slight change affecting the end of their side chains. When the coordinates of all of these residues are compared to their corresponding electron density map (EDM), all of them are correctly modeled, except for Gln189 from 6M03/6W63 and Met165 from 6M03. Then, given that the modeling of the binding site residues relative to the EDM is better in 6LU7 than in 6M03 or 6W63, we performed all our protein-ligand docking runs with 6LU7 as the target structure. Moreover, considering that: (1) our structural analysis has shown that the M-pro binding site has very limited flexibility; (2) the most flexible residues are Met49/Arg188 (S~2~ subsite) and Met165/Gln189 (S~3~ subsite); (3) the S~1~' pocket is rigid; and (4) in the S~1~ subsite changes only slightly at the end of the Ser1 and Asn142 side chains; we have decided that the receptor binding site will be considered as rigid in all the protein-ligand docking runs performed in this work, and that it will only be considered to be flexible when performing a Molecular Mechanics Generalized Born model and Solvent Accessibility (MM-GBSA) calculation to minimize the hit poses that succeed in the VS workflow.

2.2. Description of the Intermolecular Interactions between M-Pro and Cocrystallized or Predicted Inhibitors {#sec2dot2-ijms-21-03793}
------------------------------------------------------------------------------------------------------------

Until now, four M-pro inhibitors have been cocrystallized with M-pro \[[@B8-ijms-21-03793],[@B9-ijms-21-03793],[@B27-ijms-21-03793]\]. Three of these cocrystallized ligands (i.e., **13a**, **13b** and **N3**) are irreversible inhibitors that bind to M-pro through a covalent bond with Cys145, while the fourth (i.e., **X77**) is a reversible inhibitor. [Table 2](#ijms-21-03793-t002){ref-type="table"} shows the intermolecular interactions between M-pro and these four ligands. [Table 3](#ijms-21-03793-t003){ref-type="table"} shows a summary of the relevance of each binding site residue in the intermolecular interactions between M-pro and the docked poses of the top 30% compounds with the highest M-pro predicted affinity from four reference libraries \[a general anti-SARS library (i.e., OTAVA-ML-SARS) and three libraries containing predicted M-pro inhibitors (i.e., OTAVA-SARS-CoV-2, COVID-Moonshot and DD-top-1000 \[[@B5-ijms-21-03793]\]\]. A comparison of [Table 2](#ijms-21-03793-t002){ref-type="table"} and [Table 3](#ijms-21-03793-t003){ref-type="table"} reveals that the following interactions are common between cocrystallized ligands and the docked poses obtained for the compounds in the reference libraries and, therefore, may constitute important interactions:S~3~ and S~2~ subsites:In the four experimental complexes, Met165 and Gln189 pin the ligand from both sides at the S~3~ subsite through hydrophobic interactions, with Gln189 interacting with two of its side chain carbons (i.e., CG and CB) and Met165 interacting with two of its side chain atoms (i.e., CB and SD; see [Table 2](#ijms-21-03793-t002){ref-type="table"} and [Figure 3](#ijms-21-03793-f003){ref-type="fig"}). Most of the compounds in the reference libraries also interact with Met165 and Gln189 (see [Table 3](#ijms-21-03793-t003){ref-type="table"}). His41, Met49 and Asp187 also present hydrophobic interactions with most of the ligands around this area (see [Table 2](#ijms-21-03793-t002){ref-type="table"} and [Figure 3](#ijms-21-03793-f003){ref-type="fig"}). Met49 interacts with the ligands via its side chain atoms (i.e., CB, CG, SD and CE), whereas Asp187 and His41 use their CB carbon atom. [Table 3](#ijms-21-03793-t003){ref-type="table"} also shows that His41 and Met49 are highly important in the intermolecular interactions with the compounds from the reference libraries (with a more modest role for Asp187). Therefore, all these hydrophobic interactions would act as a hydrophobic grip around the same ligand group and greatly contribute to its binding affinity, which would explain the presence of the highly hydrophobic groups that the cocrystallized ligands present in this position (i.e., cyclohexylmethyl for **13a**, cyclopropylmethyl for **13b**, isopropylmethyl for **N3** and t-butyl for **X77**; see [Figure 3](#ijms-21-03793-f003){ref-type="fig"}).The carbonyl oxygen of His164 (a residue close to the previously described hydrophobic region) provides an anchor point for **13b**, **N3** and **X77** by acting as a hydrogen bond acceptor (see [Table 2](#ijms-21-03793-t002){ref-type="table"} and [Figure 3](#ijms-21-03793-f003){ref-type="fig"}). The interaction with His164 also seems important for a high percentage of docked poses in the COVID-Moonshot and DD-top-1000 reference libraries (see [Table 3](#ijms-21-03793-t003){ref-type="table"}).S~1~ subsite:In the S~1~ subsite, the carboxylic acid group of Glu166 is able to establish either a hydrogen bond interaction with **13b** or a salt bridge with **N3**. Moreover, its main chain oxygen and nitrogen (both oriented towards the S~3~ subsite) are able to act respectively as a hydrogen bond acceptor with ligands **13a**, **13b** and **N3** or as a hydrogen bond donor with all the ligands (see [Table 2](#ijms-21-03793-t002){ref-type="table"} and [Figure 3](#ijms-21-03793-f003){ref-type="fig"}). Therefore, the high number of interactions between this residue and different parts of the ligand suggest that it plays a key role in the binding of compounds. In fact, at least half of the compounds in the four reference libraries interact with this residue (see [Table 3](#ijms-21-03793-t003){ref-type="table"}).The oxygen main chain of Phe140 is able to establish a hydrogen bond with ligands **13a**, **13b** and **N3** (see [Table 2](#ijms-21-03793-t002){ref-type="table"} and [Figure 3](#ijms-21-03793-f003){ref-type="fig"}), but few docked poses in the reference libraries interact with this residue (see [Table 3](#ijms-21-03793-t003){ref-type="table"}).The side chain of His163 is able to effect hydrogen bond interactions with **13a** and **X77** (see [Table 2](#ijms-21-03793-t002){ref-type="table"} and [Figure 3](#ijms-21-03793-f003){ref-type="fig"}), but few docked poses in the reference libraries interact with this residue (see [Table 3](#ijms-21-03793-t003){ref-type="table"}).S~1~′ subsite:In the S~1~′ subsite, **13a**, **13b** and **N3** bind covalently to the catalytic residue Cys145, and **13b** and **N3** effect a hydrogen bond interaction with the NE2 atom of His41 (see [Table 2](#ijms-21-03793-t002){ref-type="table"} and [Figure 3](#ijms-21-03793-f003){ref-type="fig"}). As Cys145 and His41 constitute the catalytic dyad of M-pro, interacting with these residues may be key to establishing a strong binding with this enzyme. Although few of the docked poses of the compounds in the four reference libraries interact with Cys145, most of them interact with His41 (see [Table 3](#ijms-21-03793-t003){ref-type="table"}).In addition, the main chain nitrogen atom of Gly143 effects hydrogen bond interactions with all the cocrystallized ligands, and many compounds in the reference libraries also interact with this residue (see [Table 2](#ijms-21-03793-t002){ref-type="table"} and [Table 3](#ijms-21-03793-t003){ref-type="table"} and [Figure 3](#ijms-21-03793-f003){ref-type="fig"}). Interacting with Gly143 may be important to orient the compound towards the S~1~' subsite and stabilize the binding of the compound in the catalytic site.

Overall, three main regions can be highlighted in the M-pro binding site based on the analysis of crystallized protein-ligand complexes: (1) a hydrophobic pocket formed by the S~3~ and S~2~ subsites, in which a set of hydrophobic interactions by the residues Gln189, Met165, Met49, Asp187 and His41 (together with a hydrogen bond interaction with the main chain carbonyl oxygen of His164), contribute to a hydrophobic grip of the ligand; (2) the S~1~ pocket, in which Glu166 uses its main chain nitrogen and oxygen atoms to effect hydrogen bond interactions with all the cocrystallized ligands; and (3) the S~1~' subsite, to which the ligand is fixed by covalent and noncovalent interactions with the residues Cys145 and His41 of the catalytic dyad and a hydrogen bond interaction with the Gly143 main chain nitrogen.

2.3. Virtual Screening of Approved Drugs {#sec2dot3-ijms-21-03793}
----------------------------------------

In order to identify inhibitors that could bind to the binding site of M-pro, in the VS developed herein, we analyzed the results of three different protein-ligand programs (i.e., Glide, FRED and AutoDock Vina) and compared them to obtain the docked poses that could be obtained simultaneously with all of them. Glide, FRED and AutoDock Vina follow different approaches to generate docked poses and score the results. Glide and FRED use different exhaustive algorithms to obtain docked poses, while AutoDock Vina uses an iterated local search global optimizer \[[@B28-ijms-21-03793],[@B29-ijms-21-03793]\]. Regarding their scoring functions, while the Glide and FRED scoring functions are fully empirical \[[@B30-ijms-21-03793],[@B31-ijms-21-03793]\], the scoring function of AutoDock Vina is a hybrid scoring function that incorporates empirical and knowledge-based elements \[[@B32-ijms-21-03793]\]. Because of the differences between these three protein-ligand docking programs, both in their search algorithms and scoring functions, focusing on their intersection should compensate for their individual weaknesses \[[@B33-ijms-21-03793],[@B34-ijms-21-03793]\]. With this in mind, we designed a VS (see [Figure 4](#ijms-21-03793-f004){ref-type="fig"}) that consisted of the following three steps: (1) performing independent protein-ligand docking simulations with Glide, FRED and AutoDock Vina; (2) identifying equivalent docked poses among the three docking programs (referred to as triplets for simplicity); and (3) applying a docking score threshold to consider as VS hits only the equivalent docked poses with high affinity for M-pro. Then, if at least one of the three equivalent poses that form a triplet has a higher positive docking score than the corresponding threshold value, then this triplet is removed from the VS hits list. Also, if more than one triplet was found for the same hit, the one that presented the highest mean docking score was chosen. Finally, the Glide pose of each VS hit triplet was submitted to an energy minimization with the binding site of M-pro by using the MM-GBSA minimization available at Prime \[[@B35-ijms-21-03793]\].

After applying the VS to two libraries of approved drugs (i.e., eDrug3D and Reaxys-marketed), seven potential M-pro inhibitors were identified: Perampanel, Carprofen, Celecoxib, Alprazolam, Trovafloxacin, Sarafloxacin and ethyl biscoumacetate (see [Table 4](#ijms-21-03793-t004){ref-type="table"}). The three equivalent docked poses that presented the highest mean docking score for each hit compound and the result of the MM-GBSA minimization of the corresponding Glide pose at the M-pro binding site are shown in [Figure 5](#ijms-21-03793-f005){ref-type="fig"}. Interestingly, the docking scores obtained for our hit compounds were comparable to the four reference libraries of compounds designed specifically to inhibit M-pro (see [Figure 5](#ijms-21-03793-f005){ref-type="fig"} and [Figure 6](#ijms-21-03793-f006){ref-type="fig"}). Although higher docking score values were obtained for many compounds in the DD-top-1000 library (see [Figure 6](#ijms-21-03793-f006){ref-type="fig"}D), the compounds at the eDrug3D and Reaxys-marketed libraries offer the advantage of having already been approved, and they should be ready to be used in a shorter period of time, which is crucial now that an urgent pharmacological treatment is needed for COVID-19. A description of the seven drugs that we predict as potential M-pro inhibitors and their predicted intermolecular interactions with M-pro is shown below.

Perampanel is an AMPA glutamate receptor antagonist used as an anticonvulsant to treat partial-onset seizures (see [Table 4](#ijms-21-03793-t004){ref-type="table"}). Docking and energy minimization predict that Perampanel can interact with several residues of the S~3~, S~2~, S~1~, and S~1~' subsites (see [Table 5](#ijms-21-03793-t005){ref-type="table"}). In the predicted binding mode, its 2-pyridyl group effect hydrophobic interactions with Met165, Met49, Asp187 and His41 whereas the main chain oxygen of His164 establishes a hydrogen bond interaction with some hydrogen atoms from the 2-pyridyl ring (which should anchor the ligand to this pocket in a similar fashion to cocrystallized inhibitors; see [Table 5](#ijms-21-03793-t005){ref-type="table"} and [Figure 5](#ijms-21-03793-f005){ref-type="fig"}A). The 2-pyridyl group also effects a π stacking interaction with His41, further increasing the affinity of this substructure for this subpocket. Perampanel also establishes a hydrogen bond interaction with Gly143 close to the catalytic site, which is observed for all cocrystallized ligands (see [Table 2](#ijms-21-03793-t002){ref-type="table"}). In a similar way to **13b**, **N3** and **X77**, Perampanel also establishes a hydrogen bond between hydrogens of one of its aromatic rings (i.e., the phenyl ring) and the main chain oxygen of Thr26. Finally, Leu141 uses its main chain oxygen in a hydrogen bond with the 2-cyanophenyl aromatic ring. This latter hydrogen bond is not present in the cocrystallized inhibitors (see [Table 2](#ijms-21-03793-t002){ref-type="table"}) and, together with the one established by Thr26, helps to anchor Perampanel outside the hydrophobic pocket. Unfortunately, this drug presents severe side effects such as serious or life-threatening behavioral and psychiatric reactions. Considering these adverse effects, the risk-benefit ratio of this treatment option should be evaluated for COVID-19 patients at different stages of the disease after having confirmed its in vitro activity against M-pro.

Carprofen is a selective cyclooxygenase-2 (COX-2) inhibitor that was previously used as a pain reliever in the treatment of joint and postsurgical pain (see [Table 4](#ijms-21-03793-t004){ref-type="table"}). In the binding site of M-pro, the minimized docked pose of Carprofen also occupies the hydrophobic pocket, effecting hydrophobic interactions with the residues Gln189, Met49, Asp187 and His41, and a hydrogen bond interaction with the main chain oxygen of His164. Moreover, its chloro group is able to establish a halogen bond interaction with the thiol group of the residue Cys44, which is present at the end of this subpocket, and a hydrophobic interaction with its side-chain CB atom (see [Table 5](#ijms-21-03793-t005){ref-type="table"} and [Figure 5](#ijms-21-03793-f005){ref-type="fig"}B). The ring system at the core of the compound is also predicted to effect a π-π interaction with His41. Carprofen also makes two additional hydrogen bonds with the main chain nitrogen atoms from Ser144 and Cys145 (while the former is not found in cocrystallized M-pro inhibitors, the latter has been described for **13a** and **13b**). According to the DrugBank database \[[@B36-ijms-21-03793]\], this drug was withdrawn from the market in 1995 on commercial grounds. Carprofen was previously used in human medicine for over 10 years, and is approved for use in dogs. Regarding its adverse effects, Carprofen was generally well tolerated with mild adverse effects, i.e., similar to those of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs). However, NSAIDs increase the risk of cardiotoxicity \[[@B37-ijms-21-03793]\] and may worsen the course of community-acquired pneumonia \[[@B38-ijms-21-03793]\]. Recent bioactivity data obtained for this compound by the COVID Moonshot initiative shows that Carprofen has limited inhibition capacity on SARS-CoV-2 M-pro (3.97% inhibition at 50 µM; see [Table 4](#ijms-21-03793-t004){ref-type="table"}) and, therefore, could be used as a lead compound for the development of more potent inhibitors.

Celecoxib is a selective COX-2 inhibitor indicated for arthritis pain and to reduce precancerous polyps in the colon in familial adenomatous polyposis (see [Table 4](#ijms-21-03793-t004){ref-type="table"}). The minimized docked pose of Celecoxib at the M-pro binding site places its hydrophobic trifluoromethyl group in the hydrophobic pocket, although only a hydrophobic interaction with Met49 is reflected in [Table 5](#ijms-21-03793-t005){ref-type="table"}, possibly due to the smaller size of this substituent compared to those in the previous two compounds (see [Figure 5](#ijms-21-03793-f005){ref-type="fig"}C). Interestingly, the 4-sulfamoylphenyl group of this compound is predicted to occupy the S~1~ subsite and establish a hydrogen bond interaction with Asn142, which is also present in the cocrystallyzed complex structure with **X77**, as well as a hydrogen bond interaction with Leu141. Because of the anti-inflammatory actions of COX-2 inhibitors, the combination of an immunomodulatory agent, such as a thalidomide, and an anti-inflammatory agent, such as Celecoxib, has been suggested as a possible treatment of patients with severe COVID-19 pneumonia \[[@B39-ijms-21-03793]\]. Although significant concerns regarding the safety of COX-2 selective NSAIDs emerged in the early 2000s, in 2005, the FDA concluded that the benefits of Celecoxib treatment outweighed the potential risks for properly selected and informed patients \[[@B40-ijms-21-03793]\]. However, it is not advisable to administer Celecoxib or other NSAIDs to patients with previous cardiovascular events including acute myocardial infarction, coronary revascularization, or coronary stent insertion \[[@B41-ijms-21-03793]\], and NSAIDs may worsen the course of community-acquired pneumonia \[[@B38-ijms-21-03793]\]. Recent bioactivity data obtained for this compound by the COVID Moonshot initiative shows that Celecoxib has better inhibition capacity on SARS-CoV-2 M-pro than Carprofen (11.90% inhibition at 50µM; see [Table 4](#ijms-21-03793-t004){ref-type="table"}) and it could also be used as a lead compound for the development of more potent inhibitors (for instance, by improving the capacity of its analogs to establish better interactions with the hydrophobic pocket at the S~3~ and the S~2~ subsites or with S~1~').

Alprazolam acts on the receptors BNZ-1 and BNZ-2 and is used for the treatment of anxiety and panic disorders (see [Table 4](#ijms-21-03793-t004){ref-type="table"}). In the minimized predicted binding mode of Alprazolam, its phenyl group is buried in the hydrophobic pocket, thus establishing hydrophobic interactions with Met165, Gln189, Met49, Asp187 and His41; additionally, it establishes an aromatic hydrogen bond with His164 (see [Table 5](#ijms-21-03793-t005){ref-type="table"} and [Figure 5](#ijms-21-03793-f005){ref-type="fig"}D). Moreover, the core of the molecule establishes a hydrogen bond interaction with the main chain nitrogen of Gly143 and with the main chain oxygen of Glu166 (see [Table 5](#ijms-21-03793-t005){ref-type="table"} and [Figure 5](#ijms-21-03793-f005){ref-type="fig"}D). All of these interactions have been observed in cocrystallized ligands (see [Table 2](#ijms-21-03793-t002){ref-type="table"}) and should contribute to a good binding affinity. Moreover, the ring system of the phenyl moiety is also predicted to effect a π-π interaction with His41 (see [Table 5](#ijms-21-03793-t005){ref-type="table"} and [Figure 5](#ijms-21-03793-f005){ref-type="fig"}D). If the binding of Alprazolam to M-pro is confirmed, this drug could be advanced to clinical studies for COVID-19. According to the DrugBank database \[[@B36-ijms-21-03793]\], Alprazolam is mainly metabolized by CYP3A and, thus, its administration together with CYP3A inhibitors like ketoconazole and itraconazole is contraindicated.

Trovafloxacin is a broad spectrum antibiotic that inhibits DNA gyrase and topoisomerase IV (see [Table 4](#ijms-21-03793-t004){ref-type="table"}). In its predicted and minimized binding mode, the 2,4-difluorophenyl group of Trovafloxacin is buried in the hydrophobic pocket and effects hydrophobic interactions with Met165, Gln189 and Met49 (see [Table 5](#ijms-21-03793-t005){ref-type="table"} and [Figure 5](#ijms-21-03793-f005){ref-type="fig"}E). Interestingly, its carboxylic acid group is predicted to establish a hydrogen bond interaction with the main chain nitrogen of Ser144 and Cys145 (the latter also present in the complex with **13a** and **13b**; see [Table 2](#ijms-21-03793-t002){ref-type="table"}). Additionally, the side chain of Gln189 is also involved in a hydrogen bond with the core of Trovafloxacin (see [Table 5](#ijms-21-03793-t005){ref-type="table"} and [Figure 5](#ijms-21-03793-f005){ref-type="fig"}E). However, according to the DrugBank database \[[@B36-ijms-21-03793]\], this drug was withdrawn from the market due to its hepatotoxic potential, and therefore, it does not seem to be a relevant candidate for the treatment of COVID-19.

Sarafloxacin is a quinolone antibiotic (see [Table 4](#ijms-21-03793-t004){ref-type="table"}). The predicted and minimized binding mode of Sarafloxacin is very similar to that of Trovafloxacin (see [Table 5](#ijms-21-03793-t005){ref-type="table"} and [Figure 5](#ijms-21-03793-f005){ref-type="fig"}E,F). The 4-fluorophenyl group of Sarafloxacin establishes hydrophobic interactions with the residues Met165, Gln189, Met49, Asp187 and His41 in the hydrophobic pocket, and it establishes an aromatic hydrogen bond with the main chain oxygen of His164 (see [Table 5](#ijms-21-03793-t005){ref-type="table"}). The 4-fluorophenyl group also effects a π stacking interaction with His41, which should increase its affinity for this subpocket. The carboxylic acid group of Sarafloxacin is predicted to establish a hydrogen bond interaction with the side chain nitrogen from His41 and with the main chain nitrogen of Gly143 (the latter present in all cocrystallized M-pro complexes with inhibitors; see [Table 2](#ijms-21-03793-t002){ref-type="table"}). Finally, Sarafloxacin is also hydrogen bonded to the main chain oxygen of Thr190 (a situation that is also found for **N3**; see [Table 2](#ijms-21-03793-t002){ref-type="table"} and [Table 5](#ijms-21-03793-t005){ref-type="table"}). According to the DrugBank database \[[@B36-ijms-21-03793]\], Sarafloxacin was discontinued by its manufacturer before receiving approval for its use in the US and Canada. Therefore, even if its M-pro inhibitory activity is confirmed, more data about its putative adverse effects would be necessary before being considered as a candidate for the treatment of COVID-19.

Ethyl biscoumacetate is a vitamin K antagonist used as an anticoagulant (see [Table 4](#ijms-21-03793-t004){ref-type="table"}). In the predicted and minimized binding mode of ethyl biscoumacetate, one of its two 4-oxido-2-oxochromen-3-yl groups is oriented towards the hydrophobic pocket of the M-pro binding site, effecting hydrophobic interactions with Met165, Gln189, Met49 and His41, and hydrogen bond interactions with the His41 sidechain. In contrast, the other 4-oxido-2-oxochromen-3-yl group is oriented towards the S~1~' pocket, and establishes a hydrogen bond interaction with the main chain nitrogen of Gly143 that is a common anchor point for cocrystallized M-pro inhibitors (see [Table 2](#ijms-21-03793-t002){ref-type="table"} and [Table 5](#ijms-21-03793-t005){ref-type="table"} and [Figure 5](#ijms-21-03793-f005){ref-type="fig"}G). Despite effecting similar interactions to the other VS hits and cocrystallized ligands, the structure of this compound is quite different from those of the other VS hits, as it does not present a central cyclic core; instead, it presents a central carbon atom that forks into three radical groups that occupy the S~3~, S~1~' and S~1~ subsites. However, since according to the DrugBank database \[[@B36-ijms-21-03793]\], ethyl biscoumacetate was withdrawn from the market and it can produce prolonged bleeding and severe hemorrhage, the risk-benefit ratio of this treatment option should be evaluated for COVID-19 patients at different stages of the disease after having confirmed its in vitro activity against M-pro.

To summarize, all the VS hits establish similar interactions in the binding site of M-pro. Firstly, most of them contain a hydrophobic substructure buried in the hydrophobic pocket of the enzyme present in the S~3~ and S~2~ subsites (with Celecoxib interacting only with the S~2~ subsite moiety of this hydrophobic pocket). Secondly, most of them interact with residues in the S~1~' subsite, either by establishing hydrogen bond interactions with His41, Gly143, Ser144 or Cys145, or a combination of them and a π-π interaction with His41 in some cases (the exception is Celecoxib, which does not interact with the S~1~' subsite). In addition, the different structures of the compounds allow different interactions to occur that are not present in crystallized complexes, such as a hydrogen bond interaction with the main chain oxygen from Leu141 in the case of Perampanel and Celecoxib or a halogen bond interaction with Cys44 in the case of Carprofen. Interestingly, 42.7% of the compounds from the DD-top-1000 library (that, according to the three docking scores used in the present work, show the highest overall affinity for M-pro; see [Figure 6](#ijms-21-03793-f006){ref-type="fig"}D) effect intermolecular interactions with Leu141. This could therefore explain why Celecoxib (which, as mentioned, lacks some of the characteristic interactions with M-pro found in cocrystallized inhibitors and in the remaining VS hits) is able to interact with the M-pro binding site.

Independently of the possible adverse effects that may limit the fast use of some of these 7 drugs, the experimental validation of their activity against M-pro would be very useful for further research aimed at obtaining new drugs against COVID-19. For the moment, the predicted inhibition of M-pro has been experimentally proven for two out of the seven drugs (i.e., Carprofen and Celecoxib), and the remaining five have also been submitted to the COVID Moonshot initiative, in which it is expected that they will be selected for the next rounds of bioactivity testing (see [Table 4](#ijms-21-03793-t004){ref-type="table"} for their corresponding COVID Moonshot IDs). Overall, of the seven drugs predicted in our VS to inhibit M-pro, three of them (Perampanel, Celecoxib and Alprazolam) could be considered for COVID-19 clinical trials (provided that a significant inhibitory activity against M-pro was confirmed also for Perampanel and Alprazolam). However, a risk-benefit analysis of each drug must be carried out as, according to the MM-GBSA calculation of these three drugs, Perampanel displays a higher binding affinity for M-pro (ΔG~bind~ = −63.9 Kcal/mol) than Alprazolam (ΔG~bind~ = −57.6 Kcal/mol) or Celecoxib (ΔG~bind~ = −42.1 Kcal/mol), but shows the most severe adverse effects among these drugs. Although the M-pro inhibitory activity of Celecoxib is not very high, its risk--benefit ratio for COVID-19 patients is yet to be evaluated. Nevertheless, after the recent controversy on whether ibuprofen and other NSAIDs could worsen the effects of the SARS-CoV-2 virus, the last update of the WHO on the 18th of March of 2020 claimed that "based on currently available information, WHO does not recommend against the use of ibuprofen".

2.4. Selectivity of This Virtual Screening Workflow {#sec2dot4-ijms-21-03793}
---------------------------------------------------

In order to check the validity of the bioactivity predictions made by this VS workflow, we checked how it performs on a sample comprising 28 experimentally known M-pro inhibitors (see [Table S2](#app1-ijms-21-03793){ref-type="app"}) and 1600 calculated decoys. [Figure S1 and Table S2](#app1-ijms-21-03793){ref-type="app"} summarize the results obtained for each active in the VS. Two molecules could not be docked because of problems with either Omega (i.e., Disulfiram) or Glide (i.e., Ebselen). Among the remaining 26 M-pro inhibitors, only Shikonin had a triplet with all the comparisons between the three docked poses below the 1.5 Å threshold. Nevertheless, the docked poses involved in such triplet have more positive docking scores than the threshold values used for each protein-ligand docking program during the VS (see [Table S2](#app1-ijms-21-03793){ref-type="app"} and [Figure 7](#ijms-21-03793-f007){ref-type="fig"}). Therefore, none of the 26 M-pro inhibitors was recovered when using the same set up that was used for drug reposition.

Therefore, considering that the most reliable part of protein-ligand docking algorithms is their capacity to explore the hypothetical binding modes of a ligand at the binding site, we decided to identify the best triplet for each inhibitor and visually inspect the matching of the three poses without considering their docking scores. In [Figure S1](#app1-ijms-21-03793){ref-type="app"}, we show how 8 out of 24 known M-pro inhibitors (i.e., 11a, Carmofur, Dipyridamole, Oxytetracycline, PX-12, Shikonin, Sulfacetamide and Tideglusib) have a triplet with equivalent poses and upper RSMD range values at the \[1.29--2.64\] Å interval. Interestingly, other M-pro inhibitors like Cimetidine, Maribavir or Omeprazole have similar values for the upper limit of the RMSD interval (i.e., 2.55, 2.32 and 2.56 Å, respectively), but the visual inspection of their corresponding triplets shows that the docked poses that form these triplets cannot be considered equivalent. Summarizing, a RMSD threshold around 2.5 Å could be used, but then a visual inspection of the triplets should be done in order to discard those that are not formed by equivalent poses.

Finally, when this 2.5 Å threshold was applied to the docked poses of the 1600 calculated decoys, triplets were found for only for 131 decoys. Considering that no visual inspection of these 131 triplets was done, this means that in these conditions (i.e., RMSD limited to 2.5 Å and no docking score threshold applied), the enrichment factor for the VS workflow is, at least, 3.6. Globally, this shows that during the reposition of the approved drugs, we used very strict conditions and, therefore, it is expected that the rate of false positives in that VS will be very low. This is in agreement with the fact that the only two VS hits in our study that have been experimentally tested (i.e., Celecoxib and Carprofen) are SARS-CoV-2 M-pro inhibitors.

3. Materials and Methods {#sec3-ijms-21-03793}
========================

3.1. Libraries Description and Preparation {#sec3dot1-ijms-21-03793}
------------------------------------------

The following libraries of approved compounds were used for drug repositioning purposes: (a) e-Drug3D library: library of 1930 drugs and active metabolites approved by the FDA between 1939 and 2019 with a molecular weight ≤2000 Da from the database e-Drug3D \[[@B42-ijms-21-03793]\]; and (b) Reaxys-marketed library: library of 4536 drugs labeled as "marketed" in the field "Highest clinical phase" from the Reaxys database \[[@B43-ijms-21-03793]\].

The following libraries were used as a reference to establish key residue interactions and docking score cutoffs: (a) OTAVA-ML-SARS: library from OTAVA which contains 1577 compounds with predicted activity against SARS-CoV-2 based on machine learning approaches \[[@B44-ijms-21-03793]\]; (b) OTAVA-SARS-CoV-2: library from OTAVA which contains 1017 compounds with predicted activity against SARS-CoV-2 M-pro based on receptor-based VS \[[@B44-ijms-21-03793]\]; (c) COVID-Moonshot: library of 551 compounds mainly designed from cocrystallized drug fragments with SARS-CoV-2 M-pro and sent to COVID Moonshot before April 2020 \[[@B45-ijms-21-03793]\]; and (d) DD-top-1000: a set of 1000 potential ligands for M-pro recently identified by applying Deep Docking to the ZINC15 database \[[@B46-ijms-21-03793]\] and made publicly available by Ton et al. \[[@B5-ijms-21-03793]\].

Compounds to be docked using Glide \[[@B47-ijms-21-03793]\] and Autodock Vina \[[@B48-ijms-21-03793]\] were prepared using the following instructions: (1) generate one 3D conformation per compound and discard the compounds with unspecified chiralities with Omega \[[@B49-ijms-21-03793]\]; and (2) prepare the compounds for docking with LigPrep \[[@B50-ijms-21-03793]\] by generating all the possible protonation states for each compound in the pH range 7.2 ± 1.0 and the default number of tautomers while respecting the chiralities from the input geometry of each compound. Compounds to be docked using Fred \[[@B51-ijms-21-03793]\] were prepared using the following instructions: (1) set the ionization states of the compounds with *fixpka* \[[@B52-ijms-21-03793]\]; (2) enumerate tautomeric forms with *tautomer* \[[@B52-ijms-21-03793]\]; (3) assign atomic partial charges with *molcharge* \[[@B52-ijms-21-03793]\]; and (4) generate one conformation per compound and discard compounds with unspecified chiralities with Omega \[[@B49-ijms-21-03793]\].

3.2. Visual Inspection of the Fitting of Binding Site Coordinates to the Electron Density Maps {#sec3dot2-ijms-21-03793}
----------------------------------------------------------------------------------------------

The correctness of the binding site coordinates was analyzed by visual inspection of how they fit to the corresponding EDM. This was done with the help of JMol 14.30.2 \[[@B53-ijms-21-03793]\] and by using the EDMs (obtained from the PDBe at EMBL-EBI \[[@B54-ijms-21-03793]\]) and their corresponding PDB files (obtained from the PDB database \[[@B54-ijms-21-03793]\]). EDMs were displayed at 1.0 σ for all the M-pro binding site residues.

3.3. M-pro Structure Preparation, Grid Generation and Protein-ligand Docking Setup {#sec3dot3-ijms-21-03793}
----------------------------------------------------------------------------------

The structure of M-pro in complex with the inhibitor **N3** was obtained from the Protein Data Bank (PDBid 6LU7). Before its preparation for each piece of docking software, the covalent bond with **N3** was removed. Preparation was performed with different tools, depending on the docking software used. During docking, only the best docked pose was generated for the reference libraries, whereas 10 poses were generated for each tautomer and protonation state of the compounds in the libraries of approved compounds used for drug repositioning purposes. In the case of dockings with Glide, the M-pro structure was prepared with Maestro \[[@B24-ijms-21-03793]\] using Protein Preparation Wizard \[[@B55-ijms-21-03793],[@B56-ijms-21-03793],[@B57-ijms-21-03793],[@B58-ijms-21-03793]\] with the following settings: (a) hydrogens were added after removal of original hydrogens; (b) N and C termini were capped; (c) disulfide bonds were created between sulfur atoms within 3.2 Å; (d) Epik \[[@B57-ijms-21-03793]\] was used to generate probable tautomers and protonation states at a neutral pH; (e) H-bond assignment was further optimized using PROPKA \[[@B59-ijms-21-03793]\] at a default pH value; (f) all water molecules were removed from the structure; and (g) the structure was minimized with the default force field. Glide was used to generate the grid around the cavity of the protein where the compounds were supposed to bind using the **N3** inhibitor bound to 6LU7 as a reference. The center coordinates corresponded to the centroid of **N3** (−10.36, 12.46, 68.7) and the box size was set to 35 x 35 x 35 Å. Glide was used to dock the different compound libraries to the M-pro structure by: (a) using standard-precision (SP) mode, and (b) generating 1 or 10 binding poses per compound depending on the library. In the case of dockings with FRED, MakeReceptor \[[@B51-ijms-21-03793]\] was used to set up the receptor for docking by: (a) defining a box that enclosed the active site with its center coordinates and dimensions established based on the grid previously defined with Glide; (b) setting a shape potential; and (c) defining the inner and outer contours of the receptor with the default options. FRED 3.3.0.1. was used to dock the different compound libraries to the M-pro structure using the default settings to generate 1 or 10 binding poses per compound depending on the library. In the case of dockings with AutoDock Vina, AutoDockTools \[[@B60-ijms-21-03793]\] from MGL Tools 1.5.6. was used to prepare the protein structure by: (a) removing all waters, and (b) adding polar hydrogens. The grid was defined as a box of the same size and center coordinates as in the other two docking programs and AutoDock Vina 1.1.2 was used to dock the different compound libraries to the M-pro structure using the default settings to generate 1 or 10 binding poses per compound depending on the library.

3.4. Identification of Equivalent Docked Poses among the Three Protein-Ligand Docking Programs {#sec3dot4-ijms-21-03793}
----------------------------------------------------------------------------------------------

Equivalent docked poses among the three protein-ligand docking programs were identified by comparing the root mean square deviation (RMSD) between the heavy atoms of all docked poses obtained for the same tautomeric and protonation state of each molecule. If the RMSD between all possible pairs of docked poses in each triplet was less than or equal to 1.5 Å, the docked poses obtained with the three pieces of software were considered equivalent. The threshold value of 1.5 Å was chosen on the basis of visual inspection and general agreement in the literature \[[@B61-ijms-21-03793]\]. The Schrödinger script *rmsd.py* \[[@B62-ijms-21-03793]\] was used to calculate the RMSD values between poses.

3.5. Apply Docking Score Thresholds to Keep Only the Equivalent Docked Poses with the Highest Affinity for M-pro {#sec3dot5-ijms-21-03793}
----------------------------------------------------------------------------------------------------------------

The docking score thresholds chosen to select only the highest affinity equivalent poses were selected by docking the OTAVA-ML-SARS library with the same running conditions that were previously described for the approved compound libraries (with the only exception that for the OTAVA compounds only one docked pose for each tautomeric and protonation state was kept). Then, the docking score that kept only the top 30% of these compounds in each docking software (see [Figure 7](#ijms-21-03793-f007){ref-type="fig"}) was used as a threshold value to determine the minimum docking score that was regarded as indicating docked poses binding to M-pro with high affinity. These thresholds are −6.3, −7.0 and −7.5 Kcal/mol for Glide, FRED and AutoDock Vina, respectively (see [Figure 6](#ijms-21-03793-f006){ref-type="fig"}A and [Figure 7](#ijms-21-03793-f007){ref-type="fig"}).

Therefore, any of the equivalent docked poses of the approved compounds with docking scores more positive than their corresponding threshold were discarded (i.e., poses obtained with Glide, FRED or AutoDock Vina were compared, respectively with the Glide, FRED or AutoDock Vina thresholds). Then, only those approved compounds with a triplet of equivalent high affinity docked poses were considered VS hits (if more than one triplet of poses was found for the same hit, only the one that presented the highest mean docking score was chosen).

3.6. Virtual Screening Workflow Validation {#sec3dot6-ijms-21-03793}
------------------------------------------

The ability of the designed VS workflow to discern between active and nonactive molecules was evaluated by: (a) collecting from the literature all molecules with known in vitro activity as SARS-CoV-2 M-pro inhibitors (see [Table S2](#app1-ijms-21-03793){ref-type="app"}); and (b) using this set of known M-pro inhibitors to obtain a set of 1600 decoys with the *Generate DUD•E Decoys* tool (<http://dude.docking.org/generate>). The docking of these two sets of molecules was performed with the same conditions that were previously described at [Section 3.3](#sec3dot3-ijms-21-03793){ref-type="sec"} and 10 docked poses for each program were kept per tautomeric and protonation state.

3.7. Analysis of the Intermolecular Interactions between M-pro and Its Inhibitors {#sec3dot7-ijms-21-03793}
---------------------------------------------------------------------------------

The Glide pose from each VS hit triplet was submitted to the MM-GBSA methodology available in Prime \[[@B58-ijms-21-03793]\]. This methodology calculates the binding free energies (ΔG~bind~) from the predicted complexes obtained from ligand-docking simulations. During each MM-GBSA run, energy minimization was carried out to keep all protein residues frozen, except for a flexible region of 6 Å around the ligand. Otherwise, the remaining parameters used were the default values.

The coordinates of the protein-ligand complexes obtained after the MM-GBSA calculation were analyzed with the *poseviewer_interactions.py* script \[[@B24-ijms-21-03793]\] to determine the intermolecular interactions between the docked poses and the M-pro binding site. The following interactions were analyzed: hydrogen bonds (HAccep, HDonor and Ar-Hbond), halogen bonds (XBond), salt-bridge interactions (Salt), π-cation interactions (PiCat), π-π interactions (PiFace, PiEdge) and hydrophobic interactions (HPhob). A similar approach, but without the use of MM-GBSA, was used with the top 30% ligands with the highest M-pro affinity from the four reference libraries containing predicted M-pro inhibitors. For the reversible and irreversible inhibitors cocrystallized with M-pro and available from the PDB database, the intermolecular interactions were also determined by applying the *poseviewer_interactions.py* script to the corresponding PDB files.

3.8. Analysis of Known Mutations of the M-pro Gene {#sec3dot8-ijms-21-03793}
--------------------------------------------------

A set of 2223 SARS-CoV-2 complete genomes was downloaded from GISAID \[[@B23-ijms-21-03793]\]. These represented all the complete sequences with high coverage available on the 31st of March, 2020. The Wuhan-Hu-1/2019 genome (GenBank code MN908947.3) was used as a reference and for site numbering. A pairwise alignment between the M-pro gene, located between nucleotide positions 10,055 and 10,972 from the reference genome, and each of the complete genomes analyzed was obtained using the Smith-Waterman algorithm from BioPython. From these pairwise alignments, mutations from the reference genome were detected and classified as synonymous or missense mutations.

4. Conclusions {#sec4-ijms-21-03793}
==============

Finding drugs that can inhibit the infection caused by SARS-CoV-2 is an essential initial step while we wait for either herd immunity or a vaccine that can definitively stop this health emergency. Moreover, looking for such drugs among drugs that have already been approved is the fastest way to advance to clinical trials and spread their application among infected people. In this sense, computational approaches can make a great contribution by predicting which approved drugs have the best potential to be tested in vitro for COVID-19 repurposing. M-pro is an attractive target against SARS-CoV-2 because of its importance in the replication of SARS-CoV-2 virus, its conservation among other related viruses and a different cleavage specificity relative to human proteases \[[@B8-ijms-21-03793]\].

In this manuscript, we developed a new VS procedure to predict novel M-pro inhibitors among approved drugs. This new approach consists of finding compounds that are predicted simultaneously by three docking programs (Glide, FRED and AutoDock Vina) to bind in the same manner and with high affinity to the active site of SARS-CoV-2 M-pro. This way, we took advantage of the conformational sampling algorithms of the three docking programs to generate hypothetic binding modes without relying on a single scoring function to rank the results. Interestingly, this is the first published VS on SARS-CoV-2 M-pro in which at least part of its in silico results were confirmed in vitro.

We predicted that seven drugs, i.e., Perampanel, Carprofen, Celecoxib, Alprazolam, Trovafloxacin, Sarafloxacin and ethyl biscoumacetate, can bind to the active site of SARS-CoV-2 M-pro in a similar way to known M-pro reversible and irreversible inhibitors and Carprofen and Celecoxib showed inhibition of M-pro in vitro. The drugs with few adverse effects, i.e., Perampanel, Celecoxib and Alprazolam, could be considered for COVID-19 clinical trials, provided that the inhibitory activity against M-pro for Perampanel and Alprazolam is also confirmed. However, a risk-benefit analysis of each drug must be conducted. Interestingly, due to its anti-inflammatory activity, Celecoxib in combination with thalidomide has also been suggested as a possible treatment of patients with severe COVID-19 pneumonia \[[@B39-ijms-21-03793]\].

The analysis of the performance of known SARS-CoV-2 M-pro inhibitors and calculated decoys also confirms that we have applied a very strict criteria to perform the reposition of approved drugs. Therefore, it should be possible to repurpose more drugs (albeit at the risk of increasing the number of false positives) if the criteria are relaxed (i.e., using a higher RMSD threshold for the triplets and not considering the docking score threshold) and the RMSD calculation is complemented with a visual inspection of the resulting triplets. Moreover, the VS strategy we have developed could also be applied to commercial databases of nonapproved drugs to predict more putative SARS-CoV-2 M-pro inhibitors, thus increasing the number of available compounds for in vitro bioactivity assays against COVID-19. Finally, the analyses we show about interactions between M-pro and its inhibitors and the missense mutations found in the M-pro gene could be of interest for further research aimed at predicting new drugs for the treatment of COVID-19.

We thank OpenEye Scientific Software and ChemAxon Ltd. for kindly providing us with a software bursary to use their programs. We also thank OTAVAchemicals and the COVID MoonShot initiative for providing us with access to their SARS-CoV-2 targeted libraries. This manuscript has been edited by the English language service of our university.

Supplementary materials can be found at <https://www.mdpi.com/1422-0067/21/11/3793/s1> and consist on two tables and one figure. Table S1 summarizes the PDB codes for SARS-CoV-2 M-pro (updated on 30.03.20). Table S2 summarizes which compounds have been experimentally identified as M-pro inhibitors and reports their corresponding: (a) IC~50~ value; (b) inhibition index in infected cells; (c) docking scores for the best triplet; and (d) RMSD range for all the comparisons within the triplet. Figure S1 shows the 2D structure of the M-pro inhibitors reported at Table S2 and the superposition for the best triplet obtained for all of them (see the corresponding docking score values and their RMSD range values also at Table S2).
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![Superposition of the binding site residues of SARS-CoV-2 M-pro. Residues corresponding to the free enzyme (PDBid 6M03), M-pro bound to a noncovalent inhibitor (PDBid 6W63) and M-pro bound to a covalent inhibitor (PDBid 6LU7) are shown in red, blue and green, respectively. This figure was obtained with the help of the Maestro program \[[@B24-ijms-21-03793]\].](ijms-21-03793-g002){#ijms-21-03793-f002}

![Three-dimensional view of the binding site in experimental complexes between M-pro and reversible and irreversible inhibitors. Panels (**A**--**D**) correspond to complexes with **13a** (PDBid 6Y7M), **13b** (PDBid 6Y2F), **N3** (PDBid 6LU7) and **X77** (PDBid 6W63), respectively. This figure was obtained with the help of the Maestro program \[[@B24-ijms-21-03793]\].](ijms-21-03793-g003){#ijms-21-03793-f003}

![General scheme of the workflow used for approved-drug reposition. VS screening steps are shown against a yellow background to distinguish them from preparation or results postprocessing steps.](ijms-21-03793-g004){#ijms-21-03793-f004}

###### 

Panels (**A**--**G**) show results for Perampanel, Carprofen, Celecoxib, Alprazolam, Trovafloxacin, Sarafloxacin and Ethyl biscoumacetate; respectively. For each predicted M-pro inhibitor, the figure shows: (**A**) the superposition of the three equivalent docked poses (if more than one was found for the same hit, the one that presented the highest mean docking score was chosen); and (**B**) the corresponding Glide docked pose after the MM-GBSA minimization. Docking score values obtained with Glide, FRED and AutoDock Vina are shown in the same color as the equivalent pose obtained with the corresponding program. The ∆G~bind~ energy value obtained after the MM-GBSA minimization of the Glide pose is also shown for each predicted inhibitor. This figure was obtained with the help of the Maestro program \[[@B24-ijms-21-03793]\].
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![Histograms corresponding to the docking scores of four reference libraries containing predicted M-pro inhibitors. Panels (**A**--**D**) show the results for OTAVA-ML-SARS, OTAVA-SARS-CoV-2, COVID-Moonshot and DD-top-1000, respectively. Score thresholds for selecting the top 30% ligands with the highest affinity are shown for each histogram.](ijms-21-03793-g006){#ijms-21-03793-f006}

![General scheme of the workflow used for defining the docking score thresholds to be used to identify high affinity poses for M-pro during the VS.](ijms-21-03793-g007){#ijms-21-03793-f007}

ijms-21-03793-t001_Table 1

###### 

Synonymous and missense mutations of the M-pro gene from the analysis of 2223 complete genomes (high coverage only) available at GISAID \[[@B23-ijms-21-03793]\] on 31st March, 2020.

  Mutation   Type Mutation   AA Change
  ---------- --------------- -----------
  G10097A    missense        Gly15Ser
  C10138T    synonymous      Asn28Asn
  C10228T    synonymous      Leu58Leu
  C10232T    missense        Arg60Cys
  G10265A    missense        Gly71Ser
  C10319T    missense        Leu89Phe
  A10323G    missense        Lys90Arg
  C10369T    synonymous      Arg105Arg
  C10450T    synonymous      Pro132Pro
  T10480C    synonymous      Asn142Asn
  C10507T    synonymous      Asn151Asn
  G10523A    missense        Val157Ile
  C10572T    missense        Ala173Val
  C10582T    synonymous      Asp176Asp
  C10604T    missense        Pro184Ser
  C10632T    missense        Ala193Val
  C10641T    missense        Thr196Met
  C10712T    missense        Leu220Phe
  C10728T    missense        Thr225Ile
  C10741T    synonymous      Asp229Asp
  T10763C    missense        Tyr237His
  T10771C    synonymous      Tyr239Tyr
  C10789T    synonymous      Asp245Asp
  C10818T    missense        Ala255Val
  T10825A    synonymous      Thr257Thr
  C10834T    synonymous      Ala260Ala
  C10851T    missense        Ala266Val
  G10870T    synonymous      Leu272Leu
  A10874G    missense        Asn274Asp
  A10912G    synonymous      Leu286Leu
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###### 

Summary of the intermolecular interactions in experimental complexes between M-pro and reversible and irreversible inhibitors. These interactions were obtained by applying the *poseviewer_interactions.py* script to the corresponding PDB files.

  -----------------------------------------------------------------------------------------------------------------
  Subsite   Residue      13a\                        13b\                  N3\                X77\
                         6Y7M                        6Y2F, 6Y2G            6LU7               6W63
  --------- ------------ --------------------------- --------------------- ------------------ ---------------------
  S~3~      Met165       CB^h^, SD^h^                CB^h^, ^1^SD^h^       CB^h^,SD^h^        CB^h^

  Leu167                                                                                      

  Gln189    CG^h^        CB^h^, CG^h^                CG^h^                 CB^h^, CG^h^       

  Thr190                                             O^d^                                     

  Gln192                                                                                      

  S~2~      Met49        CE^h^, SD^h^                CE^h^, ^2^SD^h^                          CB^h^, CG^h^, SD^h^

  Tyr54                                                                                       

  His164                 O^d^                        O^d^                  O^Ar^              

  Asp187    CB^h^        CB^h^                                                                

  Arg188                                                                                      

  S~1~      Phe140       O^d^                        O^d^                  O^d^               

  Leu141                                                                                      

  Asn142                 CB^h^                                             OD1^Ar^            

  His163    NE2^a^                                                         NE2^a^             

  Glu166    N^a^, O^d^   N^a^, O^d^, OE2^d^, CG^h^   N^a^, O^d^, OE2^s^    N^a^, CB^h^        

  S~1~'     His41        CB^h^                       ^1^NE2^d^, ^1^CB^h^   CB^h^, ^3^NE2^a^   CB^h^

  Gly143    N^a^         N^a^                        N^a^                  N^a^               

  Ser144                                                                                      

  Cys145    †SG, N^a^    †SG, N^a^                   †SG, CB^h^                               

            Thr25                                                          CG2^h^             

            Thr26                                    O^Ar^                 O^Ar^              O^Ar^

            Pro168                                   ^1^CB^h^              CG^h^              

            His172                                   ^3^CD2^a^             ^3^CD2^a^          
  -----------------------------------------------------------------------------------------------------------------

^1^ only for 6Y2F; ^2^ only for 6Y2G. ^3^ An aromatic hydrogen bound to this atom is acting as hydrogen bond donor. Interactions are indicated with the protein atom that is involved, and make reference to the role played by the ligand in the intermolecular interaction with that protein atom: ^a^ HAccep, ^Ar^ Ar-Hbond, ^d^ HDonor, ^h^ HPhob and ^s^ Salt. † Interaction through a covalent bond.
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###### 

Summary of the intermolecular interactions between M-pro and the docked poses obtained by Glide of the top 30% ligands with the highest M-pro affinity from four reference libraries containing predicted M-pro inhibitors. Data shows the percentage of compounds for each library that is predicted to interact with each M-pro residue.

  Sub-Site   Residue   OTAVA-ML-SARS   OTAVA-SARS-CoV-2   COVID-Moonshot   DD-top-1000
  ---------- --------- --------------- ------------------ ---------------- -------------
  S3         Met165    88.5            91.7               67.1             66.4
  Leu167     4.2       5.8             11.4               5.9              
  Gln189     95.5      92.1            90.4               96.4             
  Thr190     9.7       14.5            15.0               11.2             
  Gln192     2.9       3.7             7.8                1.3              
  S2         Met49     74.1            78.5               67.1             68.4
  Tyr54      0.3       0.0             0.6                4.3              
  His164     17.3      18.2            49.1               76.3             
  Asp187     25.9      22.3            38.3               47.3             
  Arg188     14.1      14.0            10.2               30.5             
  S1         Phe140    12.3            7.4                14.4             18.8
  Leu141     14.4      22.7            14.4               42.7             
  Asn142     18.3      19.8            22.8               9.2              
  His163     4.5       3.3             4.8                4.8              
  Glu166     50.0      62.0            70.7               59.8             
  S1′        His41     77.7            81.0               82.6             79.9
  Gly143     42.7      49.2            24.6               78.1             
  Ser144     0.5       1.7             6.0                0.3              
  Cys145     5.2       3.7             7.8                2.3              
             Thr25     24.1            30.6               15.0             7.4
  Thr26      27.2      42.1            22.2               16.8             
  Leu27      10.7      9.9             7.8                3.8              
  Pro168     11.3      18.2            15.0               2.0              
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###### 

Main characteristics of the seven drugs predicted as SARS-CoV-2 M-pro inhibitors.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Compound                       Drugbank and COVID MoonShot IDs (with % of Inhibition at 50 µM When Available)   Status                        Mechanism                                          Indication                                                                                                Adverse Effects
  ------------------------------ -------------------------------------------------------------------------------- ----------------------------- -------------------------------------------------- --------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  ![](ijms-21-03793-i001.jpg)\   DB08883\                                                                         Approved                      AMPA glutamate receptor antagonist.                Anticonvulsant: treatment of partial-onset seizures that may or may not occur with generalized seizures   Serious or life-threatening behavioral and psychiatric reactions
  Perampanel                     \                                                                                                                                                                                                                                                                           
                                 GER-UNI-cfb                                                                                                                                                                                                                                                                 

  ![](ijms-21-03793-i002.jpg)\   DB00821\                                                                         Approved;\                    selective cyclooxygenase-2 (COX-2) inhibitor       Pain reliever in the treatment of joint pain and postsurgical pain                                        Mild, such as gastro-intestinal pain and nausea, similar to those recorded with aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDS)
  Carprofen                      \                                                                                Withdrawn ^1^                                                                                                                                                                              
                                 GER-UNI-ec7-1\                                                                                                                                                                                                                                                              
                                 \                                                                                                                                                                                                                                                                           
                                 (3.97 ± 0.60%)                                                                                                                                                                                                                                                              

  ![](ijms-21-03793-i003.jpg)\   DB00482\                                                                         Approved                      selective COX-2 inhibitor                          Arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon     Like other NSAIDS it is not advisable to administer it to patients with previous cardiovascular events
  Celecoxib                      \                                                                                                                                                                                                                                                                           
                                 GER-UNI-05c\                                                                                                                                                                                                                                                                
                                 \                                                                                                                                                                                                                                                                           
                                 (11.90 ± 0.59%)                                                                                                                                                                                                                                                             

  ![](ijms-21-03793-i004.jpg)\   DB00404\                                                                         Approved                      acts on benzodiazepine receptors BNZ-1 and BNZ-2   Treatment of anxiety and panic disorders                                                                  Generally related to its sedative effects. Mixed with alcohol it may lead to coma and death
  Alprazolam                     \                                                                                                                                                                                                                                                                           
                                 GER-UNI-cad                                                                                                                                                                                                                                                                 

  ![](ijms-21-03793-i005.jpg)\   DB00685\                                                                         Approved; Withdrawn           inhibition of DNA gyrase and topoisomerase IV.     Broad spectrum antibiotic                                                                                 It was withdrawn in 1999 due to its hepatotoxic potential.
  Trovafloxacin                  \                                                                                                                                                                                                                                                                           
                                 GER-UNI-c28                                                                                                                                                                                                                                                                 

  ![](ijms-21-03793-i006.jpg)\   DB11491\                                                                         Vet approved; Withdrawn ^2^                                                      Antibiotic                                                                                                
  Sarafloxacin                   \                                                                                                                                                                                                                                                                           
                                 GER-UNI-cae                                                                                                                                                                                                                                                                 

  ![](ijms-21-03793-i007.jpg)\   DB08794\                                                                         Withdrawn                     Vitamin K anatgonist                               Anticoagulant                                                                                             It is contraindicated in conditions like myocardial infarction, liver diseases, postpartum, hypersensitivity, pregnancy, bleeding, kidney disease, breast feeding and duodenal ulcer. It can produce increased blood clotting time, prolonged bleeding and severe hemorrhage.
  Ethyl biscoumacetate           \                                                                                                                                                                                                                                                                           
                                 GER-UNI-9e0                                                                                                                                                                                                                                                                 
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Data were obtained from DrugBank (<https://www.drugbank.ca/>). ^1^ It is no longer marketed for human usage, after being withdrawn in 1995 on commercial grounds. ^2^ It was discontinued in 2001 by its manufacturer, Abbott Laboratories, before receiving approval for use in the US and Canada.
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###### 

Summary of the intermolecular interactions between M-pro and the seven compounds that we identified as putative M-pro inhibitors. These interactions were obtained with the *poseviewer_interactions.py* script after the Glide poses and the M-pro binding site were submitted to a MM-GBSA minimization.

  Subsite   Residue   Perampanel     Carprofen             Celecoxib   Alprazolam                   Trovafloxacin   Sarafloxacin           Ethyl Biscoumacetate
  --------- --------- -------------- --------------------- ----------- ---------------------------- --------------- ---------------------- ------------------------
  S~3~      Met165    CB^h^                                            CB^h^                        CB^h^           CB^h^                  CB^h^, SD^h^
  Leu167                                                                                                                                   
  Gln189              CG^h^                                CG^h^       NE2^a^, CG^h^                CG^h^           CG^h^                  
  Thr190                                                                                            O^d^                                   
  Gln192                                                                                                                                   
  S~2~      Met49     CE^h^, SD^h^   CB^h^, CG^h^, SD^h^   SD^h^       CB^h^, CE^h^, CG^h^, SD^h^   CG^h^, SD^h^    CB^h^, CG^h^, SD^h^    SD^h^
  Tyr54                                                                                                                                    
  His164    O^Ar^     O^d^                                 O^Ar^                                    O^Ar^                                  
  Asp187    CB^h^     CB^h^                                CB^h^                                    CB^h^                                  
  Arg188                                                                                                                                   
  S~1~      Phe140                                                                                                                         
  Leu141    O^Ar^                    O^Ar^                                                                                                 
  Asn142                             OD1^d^, CB^h^                                                                  CB^h^                  
  His163                                                                                                                                   
  Glu166    CB^h^                    CB^h^                 O^Ar^       CB^h^                                                               
  S~1~'     His41     CG^p^, CB^h^   CG^p^, CG^p^, CB^h^               CG^p^, CB^h^                                 NE2^a^, CB^h^, CG^p^   NE2^a^, CD2^Ar^, CB^h^
  Gly143    N^a^                                           N^a^                                     N^a^            N^a^                   
  Ser144              N^a^                                             N^a^                                                                
  Cys145              N^a^                                             N^a^                                                                
            Thr26     O^Ar^                                                                                                                
            Cys44                    SG^x^, CB^h^                                                                                          
            Pro52                    CG^h^                                                                                                 

Interactions are indicated with the protein atom that is involved and make reference to the role played by the ligand in the intermolecular interaction with that protein atom: ^a^ HAccep, ^Ar^ Ar-Hbond, ^d^ HDonor, ^h^ HPhob, ^p^ PiFace and ^x^ XBond.

[^1]: Both authors contributed equally to this study.
